Shareholders' Equity (Details) - USD ($) $ in Thousands |
1 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Mar. 10, 2024 |
Jul. 31, 2026 |
Jun. 30, 2026 |
Apr. 30, 2026 |
Jun. 30, 2026 |
Feb. 28, 2026 |
|
| Pre-Funded Warrants [Member] | ||||||
| Shareholders’ Equity [Line Items] | ||||||
| Pre-funded warrants | 13,814 | |||||
| April 2024 Purchase Agrement [Member] | ||||||
| Shareholders’ Equity [Line Items] | ||||||
| Additional ordinary shares (in Shares) | 110,000,000 | |||||
| Registered capital shares (in Shares) | 200,000,000 | |||||
| Ordinary Shares [Member] | ||||||
| Shareholders’ Equity [Line Items] | ||||||
| Sale of ordinary shares (in Shares) | 94,858 | |||||
| Issuance of shares (in Shares) | 25,625 | 38,125 | ||||
| Warrants exercised (in Shares) | 13,814 | |||||
| Total consideration | $ 610 | |||||
| Ordinary Shares [Member] | Sales Agreement [Member] | ||||||
| Shareholders’ Equity [Line Items] | ||||||
| Aggregate net proceeds | $ 1,456 | |||||
| Ordinary Shares [Member] | RSUs [Member] | ||||||
| Shareholders’ Equity [Line Items] | ||||||
| Issuance of shares (in Shares) | 1,000 | |||||
| Ordinary Shares [Member] | Subsequent Event [Member] | ||||||
| Shareholders’ Equity [Line Items] | ||||||
| Issuance of shares (in Shares) | 12,500 | |||||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash received on stock transaction after deduction of issuance costs. No definition available.
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Number of additional shares authorized for issuance under share-based payment arrangement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|